Small molecule microarrays of RNA-focused peptoids help identify inhibitors of a pathogenic group I intron.
Peptoids that inhibit the group I intron RNA from Candida albicans, an opportunistic pathogen that kills immunocompromised hosts, have been identified using microarrays. The arrayed peptoid library was constructed using submonomers with moieties similar to ones found in small molecules known to bind RNA. Library members that passed quality control analysis were spotted onto a microarray and screened for binding to the C. albicans group I intron ribozyme. Each ligand binder identified from microarray-based screening inhibited self-splicing in the presence of 1 mM nucleotide concentration of bulk yeast tRNA with IC(50)'s between 150 and 2200 microM. The binding signals and the corresponding IC(50)'s were used to identify features in the peptoids that predispose them for RNA binding. After statistical analysis of the peptoids' structures that bind, a second generation of inhibitors was constructed using these important features; all second generation inhibitors have improved potencies with IC(50)'s of <100 microM. The most potent inhibitor is composed of one phenylguanidine and three tryptamine submonomers and has an IC(50) of 31 microM. This compound is 6-fold more potent than pentamidine, a clinically used drug that inhibits self-splicing. These results show that (i) modulators of RNA function can be identified by designing RNA-focused chemical libraries and screening them via microarray; (ii) statistical analysis of ligand binders can identify features in leads that predispose them for binding to their targets; and (iii) features can then be programmed into second generation inhibitors to design ligands with improved potencies.
Labuda
Lucas P
LP
Department of Chemistry and The Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, 657 Natural Sciences Complex, Buffalo, NY 14260, USA.
Pushechnikov
Alexei
A
Disney
Matthew D
MD
D000818:Animals; D001665:Binding Sites; D002176:Candida albicans / Q000187:drug effects* / Q000201:enzymology / Q000472:pathogenicity; D004305:Dose-Response Relationship, Drug; D007438:Introns / Q000235:genetics*; D008024:Ligands; D008968:Molecular Conformation; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D019151:Peptide Library; D034444:Peptoids / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology*; D045363:Pneumocystis carinii / Q000187:drug effects / Q000235:genetics; D012326:RNA Splicing / Q000187:drug effects; D016337:RNA, Catalytic / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics; D012331:RNA, Fungal / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics; D012343:RNA, Transfer / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics; D016808:Tetrahymena thermophila / Q000187:drug effects / Q000235:genetics
D008024:Ligands; D019151:Peptide Library; D034444:Peptoids; D016337:RNA, Catalytic; D012331:RNA, Fungal; D012343:RNA, Transfer